Back to Search Start Over

Genetic determinants of circulating sphingolipid concentrations in European populations.

Authors :
Andrew A Hicks
Peter P Pramstaller
Asa Johansson
Veronique Vitart
Igor Rudan
Peter Ugocsai
Yurii Aulchenko
Christopher S Franklin
Gerhard Liebisch
Jeanette Erdmann
Inger Jonasson
Irina V Zorkoltseva
Cristian Pattaro
Caroline Hayward
Aaron Isaacs
Christian Hengstenberg
Susan Campbell
Carsten Gnewuch
A Cecilej W Janssens
Anatoly V Kirichenko
Inke R König
Fabio Marroni
Ozren Polasek
Ayse Demirkan
Ivana Kolcic
Christine Schwienbacher
Wilmar Igl
Zrinka Biloglav
Jacqueline C M Witteman
Irene Pichler
Ghazal Zaboli
Tatiana I Axenovich
Annette Peters
Stefan Schreiber
H-Erich Wichmann
Heribert Schunkert
Nick Hastie
Ben A Oostra
Sarah H Wild
Thomas Meitinger
Ulf Gyllensten
Cornelia M van Duijn
James F Wilson
Alan Wright
Gerd Schmitz
Harry Campbell
Source :
PLoS Genetics, Vol 5, Iss 10, p e1000672 (2009)
Publication Year :
2009
Publisher :
Public Library of Science (PLoS), 2009.

Abstract

Sphingolipids have essential roles as structural components of cell membranes and in cell signalling, and disruption of their metabolism causes several diseases, with diverse neurological, psychiatric, and metabolic consequences. Increasingly, variants within a few of the genes that encode enzymes involved in sphingolipid metabolism are being associated with complex disease phenotypes. Direct experimental evidence supports a role of specific sphingolipid species in several common complex chronic disease processes including atherosclerotic plaque formation, myocardial infarction (MI), cardiomyopathy, pancreatic beta-cell failure, insulin resistance, and type 2 diabetes mellitus. Therefore, sphingolipids represent novel and important intermediate phenotypes for genetic analysis, yet little is known about the major genetic variants that influence their circulating levels in the general population. We performed a genome-wide association study (GWAS) between 318,237 single-nucleotide polymorphisms (SNPs) and levels of circulating sphingomyelin (SM), dihydrosphingomyelin (Dih-SM), ceramide (Cer), and glucosylceramide (GluCer) single lipid species (33 traits); and 43 matched metabolite ratios measured in 4,400 subjects from five diverse European populations. Associated variants (32) in five genomic regions were identified with genome-wide significant corrected p-values ranging down to 9.08x10(-66). The strongest associations were observed in or near 7 genes functionally involved in ceramide biosynthesis and trafficking: SPTLC3, LASS4, SGPP1, ATP10D, and FADS1-3. Variants in 3 loci (ATP10D, FADS3, and SPTLC3) associate with MI in a series of three German MI studies. An additional 70 variants across 23 candidate genes involved in sphingolipid-metabolizing pathways also demonstrate association (p = 10(-4) or less). Circulating concentrations of several key components in sphingolipid metabolism are thus under strong genetic control, and variants in these loci can be tested for a role in the development of common cardiovascular, metabolic, neurological, and psychiatric diseases.

Subjects

Subjects :
Genetics
QH426-470

Details

Language :
English
ISSN :
15537390 and 15537404
Volume :
5
Issue :
10
Database :
Directory of Open Access Journals
Journal :
PLoS Genetics
Publication Type :
Academic Journal
Accession number :
edsdoj.630ba93c59ca4f4f8f8c46c77baec03e
Document Type :
article
Full Text :
https://doi.org/10.1371/journal.pgen.1000672